Early Clinical Evaluation of Potential Synergy of Targeted Radiotherapy with Lintuzumab-Ac225 and Venetoclax in Relapsed/Refractory AML

Schiller, Gary J.; Finn, Laura; Hegazi, Mohamed M.; Orozco, Johnnie J.; Desai, Avinash; Chen, Mary M; Roboz, Gail J.

doi:10.1182/blood-2022-157588

Search citation statements

Order By: Relevance

Paper Sections

Select...

Cd33 and Cd1231

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preliminarily, median OS for all patients is 1 year, and 29% of patients proceeded to HCT. A phase 1 study of Actimab-A + Ven in R/R AML is also underway based on preclinical observations that lintuzumab-Ac225 promotes degradation MCL1, an anti-apoptotic protein that can mediate resistance to Ven inhibition of BCL-2 [14].…”

Section: Cd33 and Cd123mentioning

confidence: 99%

Immunotherapy for Acute Myeloid Leukemia: Current Trends, Challenges, and Strategies

Chen,

Garcia

2023

Acta Haematol

View full text Add to dashboard Cite

Background: In the past decade, there have been significant breakthroughs in immunotherapies for B-cell lymphoid malignancies and multiple myeloma, but progress has been much less for acute myeloid leukemia (AML). Nevertheless, challenge begets innovation and several therapeutic strategies are under investigation. Summary: In this review, we review the state of the art in AML immunotherapy including CD33- and CD123-targeted agents, immune checkpoint inhibition, and adoptive cell therapy strategies. We also share conceptual frameworks for approaching the growing catalog of investigational AML immunotherapies and propose future directions for the field. Key Messages: Immunotherapies for AML face significant challenges but novel strategies are in development.

show abstract

Section: Cd33 and Cd123mentioning

confidence: 99%